Stock EMBI SKYE BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
13.02 USD +0.23% Intraday chart for Skye Bioscience, Inc. +0.15% +378.68%
Apr. 23 Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index CI
Apr. 12 Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index
CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index
CI
Skye Bioscience Uplists to The Nasdaq Global Market
AQ
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K
PU
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating
MT
Skye Bioscience, Inc. announced that it has received $40 million in funding
CI
Skye Bioscience Announces $40 Million Private Placement Equity Financing
NE
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding
CI
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
AQ
Skye Bioscience Announces Board Changes
CI
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
AQ
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
CI
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding
CI
Skye Bioscience to Present at Oppenheimer Investor Conference
NE
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
NE
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding
CI
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
NE
Skye Bioscience Responds to OTC Markets Promotional Policy
AQ
Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EMBI Stock
  4. News Skye Bioscience, Inc.